In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion Pharmaceuticals Ltd.

http://www1.actelion.com/en/index.page

Latest From Actelion Pharmaceuticals Ltd.

Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India

India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.

Policy India

Pharma Past Propels Julie Brown To GSK’s CFO Position

GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.

Executive Changes Leadership

Insmed CEO On Innovating To Compete In Rare Disease

Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.

Innovation Rare Diseases

Twist's Unconventional Approach, Adding Value One Rung At A Time

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Biosciences, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.

Business Strategies Commercial
See All

Company Information

  • Other Names / Subsidiaries
    • Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
    • CoTherix, Inc
UsernamePublicRestriction

Register